Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.
Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N. Donker M, et al. Among authors: bijker n. J Clin Oncol. 2013 Nov 10;31(32):4054-9. doi: 10.1200/JCO.2013.49.5077. Epub 2013 Sep 16. J Clin Oncol. 2013. PMID: 24043739 Clinical Trial.
Corrigendum to "Harmonization of breast cancer radiotherapy treatment planning in the Netherlands" [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26-32].
Hurkmans C, Duisters C, Peters-Verhoeven M, Boersma L, Verhoeven K, Bijker N, Crama K, Nuver T, van der Sangen M. Hurkmans C, et al. Among authors: bijker n. Tech Innov Patient Support Radiat Oncol. 2023 Jan 7;25:100196. doi: 10.1016/j.tipsro.2022.12.003. eCollection 2023 Mar. Tech Innov Patient Support Radiat Oncol. 2023. PMID: 36659912 Free PMC article.
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA. Julien JP, et al. Among authors: bijker n. Lancet. 2000 Feb 12;355(9203):528-33. doi: 10.1016/s0140-6736(99)06341-2. Lancet. 2000. PMID: 10683002 Clinical Trial.
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Bijker N, et al. J Clin Oncol. 2001 Apr 15;19(8):2263-71. doi: 10.1200/JCO.2001.19.8.2263. J Clin Oncol. 2001. PMID: 11304780 Clinical Trial.
44 results